Results from our meta-analysis similarly showed that serum ferritin [standardized mean difference (SMD): −1.25; 95% CI: −2.34, −0.16; P = 0.024] and transferrin saturation (SMD: −1.19; 95% CI: −2.34, −0.05; P = 0.042) were lower in patients with prostate cancer compared with that in controls. This evidence concerns the gene TF and prostate carcinoma.